Norgine and Jubilant Announce Discovery Collaboration in Gastrointestinal Therapeutic Area

BENGALURU, India and AMSTERDAM, October 18, 2011 /PRNewswire/ --

Norgine, a leading European speciality pharmaceutical company and Jubilant Biosys Ltd., Bengaluru based subsidiary of Jubilant  Life Sciences  Ltd, an integrated pharma & life sciences company of India,  announced today, that they have  entered into a discovery partnership. The collaboration, spanning an initial period of 3 years will provide a platform for Norgine to develop multiple targets utilising Jubilant  Biosys  integrated drug discovery platform targeting gastrointestinal diseases.

Under the terms of the agreement Jubilant shall deliver preclinical candidates to Norgine who will own all rights to further development and commercialisation of the candidates.  

Commenting on the collaboration, Sri Mosur, President and CEO, Global Drug Discovery and Development at Jubilant said: "Jubilant is very pleased to partner with Norgine, a very successful European speciality pharmaceutical company. We are confident our "accelerated discovery" platform will  enable Norgine's quest  for novel and optimal therapies in delivering affordable care to the unmet needs of patients in Europe and worldwide in the area of gastrointestinal disease".

Commenting on the collaboration, Ian Cox, Vice President of Pharmaceutical & Preclinical Development at Norgine said: "We are delighted to be collaborating with Jubilant, a company with a track record in these types of discovery programmes, and we genuinely look forward to a productive and fruitful relationship".

About Norgine

Norgine is an independent, successful European speciality pharmaceutical company that has been established for over 100 years and has a presence in all major European markets. In 2010, Norgine's net product sales were €258 million. The Company employs over 1,200 people.

Norgine's focus is the development and marketing of pharmaceutical products that address significant unmet clinical needs in therapeutic areas such as gastroenterology, hepatology and supportive care. The Company currently markets a range of products in various markets in its key therapeutic areas e.g., MOVICOL^® for the treatment of constipation and faecal impaction, MOVIPREP^® a bowel cleansing preparation, KLEAN-PREP^® for bowel preparation prior to colonoscopy, XIFAXAN^® for the treatment of travellers diarrhoea and ORAMORPH^® for the treatment of moderate to severe pain associated with cancer.

Norgine is active in research and development and currently has products in various stages of clinical development. Norgine manufactures most of its own products in Hengoed, UK and Dreux, France. For more information: http://www.norgine.com

About Jubilant

Jubilant Biosys Ltd. is a Bengaluru based subsidiary of Jubilant Life Sciences Ltd, headquartered in Noida, India. It is an integrated Pharma and Life Sciences Company providing Life Science products and services to its customers spread across 75 countries. Its subsidiary Jubilant Biosys, provides integrated drug discovery and development solutions to the global pharmaceutical industry. It is a pioneer in collaborative discovery research and development   and is engaged in multiple partnerships with global pharmaceutical industry in therapeutic areas of Oncology, CNS and CVMED. http://www.jubilantbiosys.com

Norgine Contact

Julie Hornby Winfield
Global Corporate Communications Manager
+44(0)1895-826600
[email protected]

Jubilant Contacts:

For Business
Narendra R
Email:[email protected]

For Media
Seema Ahuja
E-mail: [email protected]

SOURCE Jubilant Biosys Ltd